VYNE Therapeutics (VYNE) Stifel 2024 Immunology and Inflammation Virtual Summit summary

Company overview and strategy

• Focused on developing novel BET inhibitors for autoimmune conditions, with two main assets: VYN-201 (topical, soft drug) and VYN-202 (oral, selective BD2 inhibitor).

• VYN-201 targets tissue-specific inflammation, showing strong results in skin applications, especially vitiligo.

• VYN-202 is in phase 1a clinical trials, with plans for proof-of-concept studies in rheumatoid arthritis and psoriasis.

• Emphasis on differentiating through once-daily dosing, rapid onset, and avoiding black box warnings associated with JAK inhibitors.

• Cash position of nearly $80 million supports operations through the end of next year, covering all planned clinical milestones.

Clinical development and results

• VYN-201 demonstrated significant anti-inflammatory effects and repigmentation in vitiligo, with 80% of patients on higher doses improving in phase 1b.

• Phase 2b trial for VYN-201 is a four-arm, six-month study with three active doses and placebo, mirroring industry standards.

• VYN-202 completed the single ascending dose phase with positive safety and biomarker results; multiple ascending dose data expected this quarter.

• Proof-of-concept studies for VYN-202 in psoriasis and RA are planned to start by year-end, with results anticipated in the second half of next year.

• Both programs are designed to maximize safety and efficacy data, with longer and larger studies than typical early-stage trials.

Market opportunity and differentiation

• Vitiligo affects about 3 million in the U.S., but only 10% have historically sought treatment due to limited options.

• VYN-201 aims to be first-line or adjuvant therapy, especially for localized disease, with potential advantages over current treatments like Opzelura.

• Once-daily dosing, rapid onset, and lack of black box warnings are key differentiators.

• Success in phase 2b does not require exceeding current market leader efficacy; comparable results with better safety and convenience are sufficient.

• Most vitiligo patients have less than 10% body surface area affected, making them ideal candidates for topical therapy.